Aclaris Therapeutics Inc. (NASDAQ: ACRS) completed patient enrollment in its Phase 2 trial of bosakitug (ATI-045) for patients with moderate-to-severe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE